Generate Biomedicines Inc
Follow $GENB
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $GENB by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is GENB moving today?
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
GENB overview
Related filings and maps
Congress activity in GENB
No receipt-qualified filings found.
GENB contract awards, year to date.
Public federal awards linked to this ticker.
GENB lobbying filings, year to date.
Registered lobbying filings matched to Generate Biomedicines Inc.